Food or drug? FDA blasts Flagship-backed microbiome player’s ‘non-IND’ Covid-19 trial

Amber Tong

When Kaleido Biosciences unveiled results from a multi-center, open label, controlled clinical study testing its microbiome product in Covid-19 patients back in March, the biotech …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Food or drug? FDA blasts Flagship-backed microbiome player’s ‘non-IND’ Covid-19 trial

Amber Tong

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

The Endpoints 11 winners: Big bets on AI, new frontiers in editing, a neuro renaissance and Chinese chemistry

Novo Nordisk to decrease some insulin pen manufacturing, transition supply

Exclusive: J&J folds cardiovascular and metabolic drug unit

Cassava and its former execs settle SEC charges for ‘misleading’ Alzheimer’s drug data

FDA approves Dupixent in COPD, opening ‘next chapter’ for Sanofi and Regeneron’s bestseller

PDCs vs. ADCs: A New Frontier in Targeted Cancer Therapies and the Potential for Development Partnerships

Food or drug? FDA blasts Flag­ship-backed mi­cro­bio­me play­er’s ‘non-IND’ Covid-19 tri­al

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Food or drug? FDA blasts Flagship-backed microbiome player’s ‘non-IND’ Covid-19 trial